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cell-mediated reaction to either a specific virus or several 
viruses, some of them hepatotropic” is unwarranted on 
the evidence provided. In the authors’ own words, these 
data are “too vague or speculative” to provide any real 
insight into the enigma of the relationship of lichen 
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HOW DOES ENDOSCOPIC SCLEROTHERAPY 
ALTER SPLANCHNIC HEMODYNAMICS? 
Bourbon P, Zarski JP, Kitmacher P, Bourlard P, 
Machecourt J, Denis B, Rachail M. Esophageal varice 
sclerotherapy: influence on portal pressure and azygos 
blood flow. Gastroenterol Clin Biol 1990;14:244-247. 
ABSTRACT 
Endoscopic sclerotherapy is widely employed for 
esophageal variceal hemorrhage. However it has side 
effects and can aggravate portal hypertension by 
suppression of portosystemic shunt. The purpose of the 
present investigation was to study the effect of variceal 
thrombosis on hepatic venous pressure gradient and 
azygos blood flow. Eight alcoholic cirrhotic patients 
with a first variceal hemorrhage were included. Ac- 
cording to Child Pugh’s classification, 4 patients were 
group A, 2 group B and 2 group C. At each session 40 to 
60 ml of 1 p. 100 polidocanol were injected into the 
varices. A hemodynamic study was performed in each 
patient before and about 1 week after variceal obliter- 
ation (mean 3.3 procedures). Mean value of hepatic 
venous pressure gradient was 16.0 f 5.5 mm Hg and 
17.0 f 3.8, respectively, before sclerotherapy and after 
eradication of varices; azygos blood flow 603 * 506 
mumin before and 682 2 522 after; cardiac output was 
6.5 * 0.7 mumin before and 6.5 * 0.8 after. None of 
these differences were significant. These results 
suggest that endoscopic sclerotherapy using polido- 
canol does not change hepatic venous pressure gra- 
dient and azygos blood flow, and does not lower blood 
flow through the gastroesophageal collaterals draining 
into the azygos vein. This is consistent with the 
hypothesis that thrombosis remains localized. 
COMMENTS 
In his first report of endoscopic sclerotherapy (EST) of 
esophageal varices (EV) in 1947, Moersch suggested that 
EST may increase the risk of bleeding from gastric 
varices, and he considered that the presence of gastric 
fundal varices was a contraindication to the use of EST. 
Since then, the potential hazard of EST in aggravating 
the consequences of portal hypertension has been 
debated. The hypothesis is that EST, by occluding EV 
and, perhaps, para-EV, could thereby reduce the col- 
lateral vessels that shunt blood from the gastric veins. 
Another hazard of EST that has been suggested is the 
occurrence of thrombosis in a major vessel of the portal 
venous system, which could increase the portal venous 
pressure. 
Bourbon et al. suggested, in the work under dis- 
cussion, that EST using polidocanol did not significantly 
alter the hepatic venous pressure gradient and azygos 
blood flow in eight patients with alcoholic cirrhosis who 
had recently bled from ruptured EV. This interesting 
study deserves several comments. First, no control 
group existed. As stated by the authors, this was not 
thought possible for ethical reasons. However, it greatly 
limits the conclusions achievable because it has been 
suggested that a progressive decrease in portal pressure 
occurs after a bleeding event (1) and that portal venous 
pressure falls spontaneously in alcoholic cirrhotic pa- 
tients who have not bled from varices, especially in those 
patients who abstained from alcohol (2). Second, the 
number of patients is low, and large intraindividual 
variations were observed (e.g., portal venous pressure 
fell by 59% in one patient. Third, the use of the thermal 
dilution method for prolonged periods to detect chronic 
variations in azygos blood flow has not been established. 
This measurement is technically difficult, and the 
displacement of the catheter between serial measure- 
ments may introduce methodological errors because it is 
not clear that blood flow is measured in precisely the 
same way. Finally, the authors’ results cannot be 
extrapolated to those with other sclerosing agents 
because it has been suggested that EST with ethanol- 
amine decreases azygos blood flow by almost one fourth 
after eradication of EV (3). It has also been suggested 
that ethanolamine is superior to polidocanol for the 
eradication of EV and the prevention of rebleeding (4), 
even though it has also been suggested that the 
recurrence of EV in patients receiving EST with etha- 
nolamine is caused by incomplete obliteration of the 
venous feeders of the varices ( 5 ) .  
In three other studies, EST did not significantly alter 
portal venous pressure (6). On the other hand, several 
reports have noted gastric or ectopic variceal bleeding 
after EST (61, and it has been suggested that EST 
significantly increases the prevalence of large spleno- 
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renal shunts (7). Moreover, D’Amico et al. (8) have 
suggested that EST is an independent risk factor for the 
development of portal hypertensive gastropathy. Fi- 
nally, the role of EST in inducing portal vein thrombosis 
is debated (9, 10). 
In conclusion, some discrepancies exist between he- 
modynamic and clinical studies on the venous conse- 
quences of EST. EST appears to enhance the devel- 
opment of large shunts or congestive gastropathy and to 
occlude para-EV in some patients. On the other hand, 
EST does not have a significant effect on splanchnic 
hemodynamics. These discrepancies could be explained 
by differences in the nature of the sclerosing agents used 
and by the limitations of the hemodynamic findings in 
relation to the time of bleeding. 
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